SEC Form 4 · accession 0001209191-18-051722

Lineage Cell Therapeutics, Inc. · LCTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Sep 17, 2018

Accepted (ET)

Sep 19, 2018 · 9:07 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000876343

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Option to Purchase Common Shares^F1,F2	$2.31	Sep 17, 2018	A	1,500,000	A	—	Sep 16, 2028	Common Shares	1,500,000	1,500,000	D
Restricted Stock Units^F3,F4	—	Sep 17, 2018	A	200,000	A	—	—	Common Shares	200,000	200,000	D
Restricted Stock Units^F3,F5	—	Sep 17, 2018	A	100,000	A	—	—	Common Shares	100,000	100,000	D

F1Inducement option grant made outside the BioTime 2012 Equity incentive Plan, as amended, in reliance on the employment inducement exemption to shareholder approval provided under the New York Stock Exchange's Listed Company Manual Rule 303A.08.
F2Subject to continuous service, one quarter of the options shall vest on September 17, 2019, and the balance of the options shall vest in 36 equal monthly installments at the end of each one-month period thereafter.
F3Grant of restricted stock units under the BioTime 2012 Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one Common Share.
F4Subject to continuous service, one quarter of the restricted stock units shall vest on September 17, 2019 and the balance shall vest in twelve equal quarterly installments at the end of each quarter thereafter.
F5Subject to continuous service, the restricted stock units shall vest fully on January 1, 2019.